procarbazine

Summary

Summary: An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.

Top Publications

  1. ncbi Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD)
    Loverro Giuseppe
    Department of Obstetric and Gynecology, University of Bari, Policlinico of Bari, Italy
    Hematology 12:141-7. 2007
  2. ncbi Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?
    Volker Diehl
    University of Cologne, Joseph Stelzmann Strasse 9, 50924, Koln, Germany
    Transfus Apher Sci 37:37-41. 2007
  3. ncbi Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951
    Martin J van den Bent
    Neuro Oncology Unit, Erasmus MC Daniel den Hoed Cancer Center, PO Box 5201, 3008AE Rotterdam, The Netherlands
    J Clin Oncol 31:344-50. 2013
  4. ncbi Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma
    Michael Brada
    The Institute of Cancer Research and The Royal Marsden National Health Service Foundation Trust, Sutton, Surrey, United Kingdom
    J Clin Oncol 28:4601-8. 2010
  5. ncbi Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features
    Martin J van den Bent
    Department of Neurooncology, Erasmus University Medical Center Rotterdam Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cancer 97:1276-84. 2003
  6. ncbi High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study
    G Illerhaus
    Department of Haematology, University Medical Center Freiburg, Freiburg, Germany
    Ann Oncol 20:319-25. 2009
  7. pmc Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH
    J Gregory Cairncross
    J Gregory Cairncross, University of Calgary, Calgary, Alberta Luis Souhami, McGill University, Montreal, Quebec Normand J Laperriere, University of Toronto, Toronto, Ontario, Canada Meihua Wang, American College of Radiology, Philadelphia, PA Robert B Jenkins, Caterina Giannini, and Jan C Buckner, Mayo Clinic, Rochester, MN Edward G Shaw, Wake Forest School of Medicine, Winston Salem, NC David G Brachman, Arizona Oncology Services Foundation Barrow Neurological Institute, Phoenix, AZ Karen L Fink, Baylor University, Dallas, TX Jason T Huse, Memorial Sloan Kettering Cancer Center, New York, NY Minesh P Mehta, Northwestern University, Chicago, IL and Walter J Curran Jr, Emory University, Atlanta, GA
    J Clin Oncol 32:783-90. 2014
  8. ncbi Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study
    Christine Mauz-Körholz
    Department of Paediatrics, Martin Luther University of Halle Wittenberg, Halle, Germany
    J Clin Oncol 28:3680-6. 2010
  9. ncbi Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly
    K Fritsch
    Department of Hematology and Oncology, Freiburg University Medical Center, Freiburg, Germany
    Ann Oncol 22:2080-5. 2011
  10. ncbi 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group
    M Sieber
    German Hodgkin s Lymphoma Study Group, Klinik fur Innere Medizin, University of Cologne, Germany
    J Clin Oncol 21:1734-9. 2003

Research Grants

  1. LEUKOCYTE, ENZYME AND DRUG CHEMILUMINESCENCE STUDIES
    JEFFREY KANOFSKY; Fiscal Year: 1990
  2. Oral Chemotherapy in AIDS-related NHL in Uganda & Kenya
    Scot Remick; Fiscal Year: 2003
  3. ASSESSMENT OF GENETIC DAMAGE INDUCED BY CHEMOTHERAPY
    JAN LIANG; Fiscal Year: 1992
  4. MUTAGENIC ACTION OF CANCER THERAPY ON TESTIS CELLS
    Marvin Meistrich; Fiscal Year: 1992
  5. AGT DEPLETION FOR THERAPY OF CNS TUMORS
    Jennifer Quinn; Fiscal Year: 2004
  6. DNA CROSSLINK REPAIR ENZYMES IN HUMAN CELLS
    THOMAS BRENT; Fiscal Year: 1992
  7. NUCLEOPROTEINS IN MAMMALIAN SPERMATOGENESIS
    Marvin Meistrich; Fiscal Year: 2006
  8. NATIONAL GENE VECTOR LABORATORY AT INDIANA UNIVERSITY
    Kenneth Cornetta; Fiscal Year: 2007
  9. NABTC CENTRAL OPERATION GRANT (UCSF PROJECT LEADER)
    Michael Prados; Fiscal Year: 2008
  10. New Approaches to Brain Tumor Therapy, NABTT CNS
    Glenn Lesser; Fiscal Year: 2008

Detail Information

Publications210 found, 100 shown here

  1. ncbi Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD)
    Loverro Giuseppe
    Department of Obstetric and Gynecology, University of Bari, Policlinico of Bari, Italy
    Hematology 12:141-7. 2007
    ..In conclusion, ovarian reserve evaluation, in young patients treated by CHT, can be performed by AFC. GnRH-a treatment does not have a protective effect, but could delay the development of ovarian failure...
  2. ncbi Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?
    Volker Diehl
    University of Cologne, Joseph Stelzmann Strasse 9, 50924, Koln, Germany
    Transfus Apher Sci 37:37-41. 2007
    ..We certainly hope that it will not last another 20 years to establish the BEACOPP regimen as an attractive curative treatment option for at least the high risk cohorts of HL...
  3. ncbi Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951
    Martin J van den Bent
    Neuro Oncology Unit, Erasmus MC Daniel den Hoed Cancer Center, PO Box 5201, 3008AE Rotterdam, The Netherlands
    J Clin Oncol 31:344-50. 2013
    ..We now present the long-term follow-up findings of a randomized phase III study on the addition of six cycles of procarbazine, lomustine, and vincristine (PCV) chemotherapy to radiotherapy (RT).
  4. ncbi Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma
    Michael Brada
    The Institute of Cancer Research and The Royal Marsden National Health Service Foundation Trust, Sutton, Surrey, United Kingdom
    J Clin Oncol 28:4601-8. 2010
    ..No prospective comparison with nitrosourea-based chemotherapy exists. We report, to our knowledge, the first randomized trial of procarbazine, lomustine, and vincristine (PCV) versus TMZ in chemotherapy-naive patients with recurrent HGG.
  5. ncbi Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features
    Martin J van den Bent
    Department of Neurooncology, Erasmus University Medical Center Rotterdam Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cancer 97:1276-84. 2003
    ..The authors investigated the correlation between genetic and clinical characteristics of OD in 33 patients who received chemotherapy with procarbazine, lomustine, and vincristine for recurrent disease after receiving radiotherapy.
  6. ncbi High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study
    G Illerhaus
    Department of Haematology, University Medical Center Freiburg, Freiburg, Germany
    Ann Oncol 20:319-25. 2009
    ..nervous system lymphoma (PCNSL), we conducted a phase II study with high-dose methotrexate (MTX) combined with procarbazine and CCNU...
  7. pmc Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH
    J Gregory Cairncross
    J Gregory Cairncross, University of Calgary, Calgary, Alberta Luis Souhami, McGill University, Montreal, Quebec Normand J Laperriere, University of Toronto, Toronto, Ontario, Canada Meihua Wang, American College of Radiology, Philadelphia, PA Robert B Jenkins, Caterina Giannini, and Jan C Buckner, Mayo Clinic, Rochester, MN Edward G Shaw, Wake Forest School of Medicine, Winston Salem, NC David G Brachman, Arizona Oncology Services Foundation Barrow Neurological Institute, Phoenix, AZ Karen L Fink, Baylor University, Dallas, TX Jason T Huse, Memorial Sloan Kettering Cancer Center, New York, NY Minesh P Mehta, Northwestern University, Chicago, IL and Walter J Curran Jr, Emory University, Atlanta, GA
    J Clin Oncol 32:783-90. 2014
    ..Thus, 1p/19q status may not identify all responders to CRT...
  8. ncbi Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study
    Christine Mauz-Körholz
    Department of Paediatrics, Martin Luther University of Halle Wittenberg, Halle, Germany
    J Clin Oncol 28:3680-6. 2010
    ..vincristine, prednisone, and dacarbazine (COPDAC) is derived from standard vincristine, procarbazine, prednisone, and doxorubicin (OPPA)-cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) ..
  9. ncbi Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly
    K Fritsch
    Department of Hematology and Oncology, Freiburg University Medical Center, Freiburg, Germany
    Ann Oncol 22:2080-5. 2011
    ..In this article, we report the results of a pilot trial adding rituximab to the established regimen consisting of methotrexate, procarbazine, and lomustine (R-MCP).
  10. ncbi 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group
    M Sieber
    German Hodgkin s Lymphoma Study Group, Klinik fur Innere Medizin, University of Cologne, Germany
    J Clin Oncol 21:1734-9. 2003
    ..and efficacy of a time-intensified bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) regimen given in 14-day intervals (BEACOPP-14) with granulocyte colony-stimulating ..
  11. ncbi Phase II trial of radiotherapy after hyperbaric oxygenation with multiagent chemotherapy (procarbazine, nimustine, and vincristine) for high-grade gliomas: long-term results
    Kazuhiko Ogawa
    Department of Radiology, University of the Ryukyus, Okinawa, Japan
    Int J Radiat Oncol Biol Phys 82:732-8. 2012
    ..To analyze the long-term results of a Phase II trial of radiotherapy given immediately after hyperbaric oxygenation (HBO) with multiagent chemotherapy in adults with high-grade gliomas...
  12. ncbi Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome
    Patrick G Morris
    Patrick G Morris, Denise D Correa, Joachim Yahalom, Anne S Reiner, Kathy Panageas, Sasan Karimi, Richard Curry, Gaurav Shah, Lauren E Abrey, Lisa M DeAngelis, and Antonio Omuro, Memorial Sloan Kettering Cancer Center Rose K Lai, Columbia University, New York, NY Jeffrey J Raizer and Sean Grimm, Northwestern University, Chicago, IL David Schiff, University of Virginia, Charlottesville, VA and Barbara Grant, University of Vermont, Burlington, VT
    J Clin Oncol 31:3971-9. 2013
    A multicenter phase II study was conducted to assess the efficacy of rituximab, methotrexate, procarbazine, and vincristine (R-MPV) followed by consolidation reduced-dose whole-brain radiotherapy (rdWBRT) and cytarabine in primary CNS ..
  13. ncbi Fotemustine combined with procarbazine in recurrent malignant gliomas: a phase I study with evaluation of lymphocyte 06-alkylguanine-DNA alkyltransferase activity
    A Boiardi
    Istituto Carlo Besta, Milan, Italy
    J Neurooncol 52:149-56. 2001
    ..the maximum tolerated dose (MTD) and toxicity profile of fotemustine when combined with a fixed dose of procarbazine (PCZ), and to evaluate the extent of O6-alkylguanine-DNA alkyltransferase (ATase) depletion in circulating ..
  14. ncbi Early response to high-dose methotrexate, vincristine, and procarbazine chemotherapy-adapted strategy for primary CNS lymphoma: no consolidation therapy for patients achieving early complete response
    Yu Ri Kim
    Division of Hematology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, 50 Yonsei ro, Seodaemun gu, Seoul, 120 752, South Korea
    Ann Hematol 93:211-9. 2014
    ..we investigated the treatment outcomes and prognostic factors of high-dose methotrexate, vincristine, and procarbazine (MVP) chemotherapy followed by an interim response-adapted intensification strategy in immunocompetent patients ..
  15. ncbi Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)
    Teresa V Halbsguth
    First Department of Internal Medicine, University Hospital of Cologne, Cologne, Germany
    Blood 116:2026-32. 2010
    ..We thus developed a new regimen, BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone), to improve both tolerability and efficacy of treatment for older HL patients...
  16. pmc Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC stu
    Lale Erdem-Eraslan
    Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Clin Oncol 31:328-36. 2013
    ..Research and Treatment of Cancer (EORTC) 26951, a randomized phase III clinical trial investigating adjuvant procarbazine, lomustine, and vincristine (PCV) chemotherapy in anaplastic oligodendroglial tumors...
  17. ncbi Procarbazine as adjunctive therapy for treatment of dogs with presumptive antemortem diagnosis of granulomatous meningoencephalomyelitis: 21 cases (1998-2004)
    Joan R Coates
    Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia 65211, USA
    J Vet Intern Med 21:100-6. 2007
    ..Remission often is short-lived in dogs treated with glucocorticoids. Procarbazine is T cell-specific and crosses the blood-brain barrier.
  18. ncbi Hyperfractionated radiotherapy and multi-agent chemotherapy (procarbazine, ACNU and vincristine) for high-grade gliomas: a prospective study
    Kazuhiko Ogawa
    Department of Radiology, University of the Ryukyus, School of Medicine, 207 Uehara, Nishihara cho, Okinawa, 903 0215, Japan
    Anticancer Res 26:2457-62. 2006
    To evaluate the feasibility, efficacy and toxicity of hyperfractionated radiotherapy and multi-agent chemotherapy, including procarbazine, nimustine (ACNU) and vincristine, in adults with high-grade gliomas.
  19. ncbi Reduction of procarbazine-induced cleft palates by prenatal folic acid supplementation in rats
    Fathi A Malek
    Department of Anatomy, Ernst Moritz Arndt University, Greifswald, Germany
    Pathol Res Pract 200:33-40. 2004
    We investigated the effects of prenatal folic acid supplementation on procarbazine (PCZ)-induced intra-uterine growth retardation (IUGR), cleft palates, and microgenia...
  20. pmc A phase II trial of thalidomide and procarbazine in adult patients with recurrent or progressive malignant gliomas
    Jimmy Ruiz
    Section on Hematology and Oncology, Department of Internal Medicine, Wake Forest School of Medicine, Medical Center Boulevard, Winston Salem, NC 27157, USA
    J Neurooncol 106:611-7. 2012
    Thalidomide and procarbazine have demonstrated single agent activity against malignant gliomas (MG). We evaluated the combination of thalidomide and procarbazine with a single arm phase II trial in adults with recurrent or progressive MG...
  21. ncbi Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors
    C Walker
    J K Douglas Laboratories, Clatterbridge Hospital, Bebington, Wirral, UK
    Neurology 66:1661-7. 2006
    ..The -1p/-19q genotype has been associated with prolonged survival and chemosensitivity in oligodendroglial neoplasms, but the predictive and prognostic significance of genotype in the routine clinic is not established...
  22. ncbi Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer p
    Martin J van den Bent
    Departments of Neurology and Pathology, Daniel den Hoed Cancer Center Erasmus University Hospital, Rotterdam, The Netherlands
    J Clin Oncol 24:2715-22. 2006
    ..We investigated, in a multicenter randomized controlled trial, whether adjuvant procarbazine, lomustine, and vincristine (PCV) chemotherapy improves overall survival (OS) in newly diagnosed patients with ..
  23. ncbi Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma
    Gaurav D Shah
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:4730-5. 2007
    ....
  24. ncbi Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404
    Michael D Prados
    Department of Neurosurgery, University of California, San Francisco, 94143 0372, USA
    Int J Radiat Oncol Biol Phys 58:1147-52. 2004
    ..anaplastic glioma other than glioblastoma multiforme comparing external beam radiotherapy (EBRT) plus adjuvant procarbazine, cyclohexylchloroethylnitrosurea (lomustine), and vincristine (PCV) chemotherapy with or without ..
  25. ncbi Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402
    Gregory Cairncross
    University of Calgary, Calgary, Alberta, Canada E mail
    J Clin Oncol 24:2707-14. 2006
    ..oligoastrocytoma (AOA) are treated with surgery and radiotherapy (RT) at diagnosis, but they also respond to procarbazine, lomustine, and vincristine (PCV), raising the possibility that early chemotherapy will improve survival...
  26. ncbi Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme
    D Osoba
    Quality of Life Consulting, Vancouver, British Columbia, Canada
    J Clin Oncol 18:1481-91. 2000
    To determine whether chemotherapy with temozolomide (TMZ) versus procarbazine (PCB) for recurrent glioblastoma multiforme (GBM) was associated with improvement in health-related quality of life (HRQOL).
  27. ncbi Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: A retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy
    M D Prados
    Department of Neurosurgery, University of California San Francisco, San Francisco, CA 94143 0372, USA
    J Clin Oncol 17:3389-95. 1999
    To determine any differences in outcome for patients with anaplastic astrocytoma (AA) treated with adjuvant carmustine (BCNU) versus procarbazine, lomustine, and vincristine (PCV) chemotherapy.
  28. ncbi NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide
    Wolfgang Wick
    Department of Neurology and Hertie Institute for Clinical Brain Research, University of Tubingen, Tubingen, Germany
    J Clin Oncol 27:5874-80. 2009
    ..The NOA-04 phase III trial compared efficacy and safety of radiotherapy followed by chemotherapy at progression with the reverse sequence in patients with newly diagnosed anaplastic gliomas...
  29. ncbi Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis
    Herbert H Engelhard
    Department of Neurosurgery, The University of Illinois at Chicago, Chicago, Illinois 60612, USA
    Surg Neurol 60:443-56. 2003
    ..In this article, the topic of oligodendroglioma and anaplastic oligodendroglioma is reviewed, highlighting the new clinical developments...
  30. ncbi Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a phase II study
    Alba A Brandes
    Department of Medical Oncology, Azienda Ospedale Universita, Padova, Italy
    Oncology 63:38-41. 2002
    ..TTP), response rate and toxicity, a phase II study was conducted in patients with recurrent glioblastoma multiforme (GBM) following surgery plus radiotherapy and a first-line regimen based on nitrosourea, procarbazine and vincristine.
  31. ncbi Benefit of temozolomide compared to procarbazine in treatment of glioblastoma multiforme at first relapse: effect on neurological functioning, performance status, and health related quality of life
    David R Macdonald
    MEDTAP International, London, UK
    Cancer Invest 23:138-44. 2005
    ..the value of multiple outcome measures using the results of a recent clinical trial comparing temozolomide with procarbazine in the treatment of Glioblastoma Multiforme...
  32. ncbi The complex clinical picture of presumably allergic side effects to cytostatic drugs: symptoms, pathomechanism, reexposure, and desensitization
    Mauro Pagani
    Allergology and Oncology Service, Medicine Department, Asola Hospital, Mantova, Italy
    Med Clin North Am 94:835-52, xiii. 2010
    ..Hypersensitivity reactions are common with platinum compounds, L-asparaginase, taxanes, procarbazine, and epipodophyllotoxins, whereas they are unusual, but always possible, with the other chemotherapeutic drugs...
  33. ncbi Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities
    Jan C Buckner
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 21:251-5. 2003
    ....
  34. ncbi Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents
    Christina Lee
    Department of Medicine, Division of Allergy and Immunology, VA Greater Los Angeles Healthcare System University of California Los Angeles, Los Angeles, California 90073, USA
    Ann Allergy Asthma Immunol 102:179-87; quiz 187-9, 222. 2009
    ..To review clinical hypersensitivity reactions related to common cancer chemotherapy agents and to discuss potential management strategies...
  35. ncbi Treatment for primary CNS lymphoma: the next step
    L E Abrey
    Departments of Neurology and Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 18:3144-50. 2000
    ..The reported protocol was designed to optimize and enhance the chemotherapeutic component of treatment...
  36. ncbi Radiotherapy plus concurrent and adjuvant procarbazine, lomustine, and vincristine chemotherapy for patients with malignant glioma
    Seung Ho Yang
    Department of Neurosurgery, Kangnam St Mary s Hospital, The Catholic University of Korea, Seocho Gu, Seoul 137 701, Korea
    Oncol Rep 17:1359-64. 2007
    ..Both external involved field radiotherapy and chemotherapy, composed of CCNU (75-110 mg/m(2)), procarbazine (60 mg/m(2)) and vincristine (1.4 mg/m(2)), were started simultaneously two weeks after surgery...
  37. ncbi Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination o
    Henning Bredenfeld
    Department I for Internal Medicine, University Hospital Cologne, Cologne, Germany
    J Clin Oncol 22:2424-9. 2004
    ..nonleukemogenic polychemotherapy regimen, BAGCOPP (bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, gemcitabine) in a phase I/II dose-escalation study in patients with advanced-stage Hodgkin' s ..
  38. ncbi Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study
    Alba Ariela Brandes
    Department of Medical Oncology, Azienda Ospedale Università of Padova, Padova, Italy
    Cancer 101:2079-85. 2004
    ..knowledge, there is a scarcity of accurate data regarding the feasibility of standard chemotherapy with procarbazine, lomustine, and vincristine (PCV) in a homogeneous series of patients with primary anaplastic oligodendroglioma ..
  39. ncbi Plasma kinetics of procarbazine and azo-procarbazine in humans
    Rainer Preiss
    Institute of Clinical Pharmacology, University of Leipzig, Leipzig, Germany
    Anticancer Drugs 17:75-80. 2006
    The plasma kinetics of procarbazine (PCB) and its major metabolite azo-procarbazine (azo-PCB) were systematically investigated in humans for the first time...
  40. pmc A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
    W K Yung
    Department of Neuro Oncology, UTMD Anderson Cancer Center, Box 100, 1515 Holcombe Boulevard, Houston, Texas, 77030, USA
    Br J Cancer 83:588-93. 2000
    ..open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with glioblastoma multiforme at first relapse...
  41. pmc Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951
    Mathilde C M Kouwenhoven
    Department of Neurology, Daniel den Hoed Cancer Center, Erasmus University Hospital, Rotterdam, The Netherlands
    Neuro Oncol 11:737-46. 2009
    ..III European Organisation for Research and Treatment of Cancer (EORTC) study 26951 on the effects of adjuvant procarbazine, chloroethyl cyclohexylnitrosourea (lomustine), and vincristine chemotherapy in anaplastic oligodendroglial ..
  42. ncbi Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10
    Lisa M DeAngelis
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:4643-8. 2002
    ..Cranial irradiation alone rarely results in long-term disease control or prolonged survival. We prospectively studied the use of combination chemotherapy plus cranial irradiation in newly diagnosed patients with PCNSL...
  43. ncbi Role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone
    Jana Markova
    Department of Clinical Hematology, University Hospital Kralovske Vinohrady, Third Faculty of Medicine, Charles University, Prague, Czech Republic
    Leuk Lymphoma 53:64-70. 2012
    ..Interim PET after four cycles of bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone (BEACOPP) is a strong prognostic marker for PFS in advanced HL.
  44. ncbi Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen
    M D Prados
    Department of Neurological Surgery, School of Medicine, University of California, San Francisco, USA
    J Neurooncol 32:235-41. 1997
    ..b>Procarbazine, 6-thioguanine, and dibromodulcitol were given before lomustine (CCNU) and vincristine was given 1 and 3 weeks ..
  45. ncbi Initial chemotherapy in gliomatosis cerebri
    M Sanson
    Fédération de Neurologie Mazarin, Groupe hospitalier Pitié Salpêtrière and Université Pierre et Marie Curie, Paris, France
    Neurology 63:270-5. 2004
    ..Because of the diffuse nature of gliomatosis cerebri (GC), surgery is not suitable, and large field radiotherapy carries the risk of severe toxicity. In this setting, initial chemotherapy warrants further investigation...
  46. ncbi Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972
    M J van den Bent
    Department of Neuro Oncology, University Hospital Rotterdam Rotterdam Cancer Center, The Netherlands
    Ann Oncol 14:599-602. 2003
    ..tumors are chemosensitive, with two-thirds of patients responding to PCV combination chemotherapy with procarbazine, lomustine (CCNU) and vincristine...
  47. pmc Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas
    E S Newlands
    Imperial College School of Medicine, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, UK
    Br J Cancer 89:248-51. 2003
    ..b>Procarbazine (PCB) has been used for treating gliomas for many years and here both agents were combined in the treatment...
  48. ncbi Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients
    Antonio Silvani
    Department of Neuro Oncology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
    J Neurooncol 87:143-51. 2008
    The purpose of this study was to evaluate safety and efficacy of Procarbazine (PCB) and fotemustine (FTM) combination in the treatment of pre-temozolomide treated, recurrent GBM patients...
  49. ncbi Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients
    A J Ferreri
    Department of Radiochemotherapy, San Raffaele H Scientific Institute, Milan, Italy
    Oncology 60:134-40. 2001
    ....
  50. pmc Factors influencing the response to high dose methotrexate-based vincristine and procarbazine combination chemotherapy for primary central nervous system lymphoma
    Kang Hyun Sung
    Department of Neurosurgery and Division of Neurooncology, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, 158 Paryong ro, Masanhoewon gu, Changwon, Korea
    J Korean Med Sci 26:551-60. 2011
    ..5 g/m(2)) and vincristine (1.4 mg/m(2)/day) for one day during weeks 1, 3, 5, 7, and 9, and procarbazine (100 mg/m(2)/day) for one week during weeks 1, 5, and 9. Forty-one patients (78...
  51. ncbi Immuno-chemotherapy with a combination of rituximab, methotrexate, pirarubicin and procarbazine for patients with primary CNS lymphoma--a preliminary report
    Ryuya Yamanaka
    Leuk Lymphoma 48:1019-22. 2007
  52. ncbi A pilot study of dose-intensified procarbazine, CCNU, vincristine for poor prognosis brain tumors utilizing fibronectin-assisted, retroviral-mediated modification of CD34+ peripheral blood cells with O6-methylguanine DNA methyltransferase
    K Cornetta
    Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, 46202, USA
    Cancer Gene Ther 13:886-95. 2006
    ..to transduce hematopoietic progenitors, which were subsequently used in the setting of alkylator therapy (procarbazine, CCNU, vincristine (PCV)) for poor prognosis brain tumors...
  53. ncbi Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy
    Morton Coleman
    Center for Lymphoma and Myeloma, Division of Hematology Oncology, Department of Medicine, Weill Cornell Medical College, New York Presbyterian Hospital, New York, New York 10021, USA
    Cancer 112:2228-32. 2008
    ..Many patients with recurrent lymphoma are unable to tolerate intensive therapies, or have disease that is refractory. Metronomic chemotherapy offers a novel, potentially less toxic yet effective treatment strategy...
  54. ncbi Sex-related differences in procarbazine-induced cleft palate and microgenia and the anti-teratogenic effect of prenatal folic acid supplementation in rats
    F A Malek
    Department of Anatomy, Ernst Moritz Arndt University, Friedrich Loeffler Strasse 23 c, D 17487 Greifswald, Germany
    Ann Anat 185:465-70. 2003
    Sex-related differences in the frequency of cleft palates and microgenia in rat fetuses prenatally treated with procarbazine (200 mg/kg on day 14 of gestation (GD14), group 1), and the anti-teratogenic effect of prenatal folic acid ..
  55. pmc Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma
    Jia Ruan
    Division of Hematology Oncology, Center for Lymphoma and Myeloma, Weill Cornell Medical College, New York, New York, USA
    Cancer 116:2655-64. 2010
    ..authors report safety, activity, and angiogenic profiling results with the rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide (RT-PEPC) regimen in patients with recurrent mantle cell lymphoma (MCL).
  56. ncbi Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme
    V A Levin
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Clin Cancer Res 6:3878-84. 2000
    Although the efficacy of the nitrosourea-based combination chemotherapy procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, and vincristine (PCV) has been previously demonstrated in the setting of anaplastic/intermediate-grade ..
  57. ncbi Efficacy of adjuvant therapy with procarbazine, MCNU, and vincristine for oligodendroglial tumors
    T Wakabayashi
    Department of Neurosurgery, Nagoya University School of Medicine, Nagoya
    Neurol Med Chir (Tokyo) 41:115-9; discussion 119-20. 2001
    An adjuvant chemotherapy regimen consisting of procarbazine, MCNU, and vincristine (PMV) was evaluated for the treatment of malignant oligodendroglial tumors...
  58. ncbi Prospective trial of radiotherapy after hyperbaric oxygenation with chemotherapy for high-grade gliomas
    Kazuhiko Ogawa
    Department of Radiology, University of the Ryukyus, School of Medicine, 207 Uehara, Nishihara cho, 903 0215, Okinawa, Japan
    Radiother Oncol 67:63-7. 2003
    ..The current study indicated that radiotherapy immediately after HBO with chemotherapy was feasible for high-grade gliomas...
  59. ncbi Effects of prenatal procarbazine administration on intrauterine development in rats
    F A Malek
    Department of Anatomy, Ernst Moritz Arndt University, Friedrich Loeffler Strasse 23c, D 17487 Greifswald, Germany
    Ann Anat 185:117-9. 2003
    The effects of prenatal procarbazine (PCZ) administration on the intrauterine development of rat fetuses were investigated. Gravid rats were treated on day 14 of gestation (GD14) with 25 mg or 50 mg/kg body weight PCZ via stomach tube...
  60. ncbi Procarbazine in haematology: an old drug with a new life?
    M Massoud
    Departement de Medecine, Institut Gustave Roussy, 39 Rue C Desmoulins, 94805 Villejuif, France
    Eur J Cancer 40:1924-7. 2004
    b>Procarbazine (PCB) was developed in the 1960s and was rapidly recognised as an active agent in lymphoid malignancies...
  61. ncbi Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine
    Elize M Biemond ter Stege
    Department of Neurology Neuro Oncology, Erasmus University Medical Center Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cancer 103:802-9. 2005
    ..The authors retrospectively studied the outcome of the procarbazine, lomustine, and vincristine (PCV) chemotherapy regimen in a group of 16 patients with newly diagnosed OD and 5 ..
  62. ncbi Procarbazine for non-Hodgkin's lymphoma
    Bassem T Chaar
    Department of Internal Medicine, Saint Louis University School of Medicine, Saint Louis, MO 63110, USA
    Leuk Lymphoma 47:637-40. 2006
    b>Procarbazine hydrochloride is an oral alkylating agent with activity against lymphoma. It is most commonly used in the treatment of Hodgkin's disease...
  63. pmc Phase II study of 6-thioguanine, procarbazine, dibromodulcitol, lomustine, and vincristine chemotherapy with radiotherapy for treating malignant glioma in children
    V A Levin
    Brain Tumor Center and the Department of Neuro Oncology, Houston, TX 77030, USA
    Neuro Oncol 2:22-8. 2000
    ..a single-arm phase II study to evaluate the efficacy and safety of radiotherapy combined with 6-thioguanine, procarbazine, dibromodulcitol, lomustine, and vincristine (TPDCV) chemotherapy for treating malignant astrocytoma in ..
  64. ncbi Response of recurrent glioblastoma and anaplastic astrocytoma to dibromodulcitol, BCNU and procarbazine--a phase-II study
    J Hildebrand
    Service de Neurologie, Hopital Erasme, ULB, Brussels, Belgium
    J Neurooncol 37:155-60. 1998
    ..70/100 were treated at recurrence with dibromodulcitol (DBD) 1400 mg/m2 on day 1, BCNU 150 mg/m2 on day 2, and procarbazine (PCZ) 150 mg/day on days 1 to 15...
  65. ncbi Procarbazine genotoxicity in the MutaMouse; strong clastogenicity and organ-specific induction of lacZ mutations
    T Suzuki
    Division of Genetics and Mutagenesis, National Institute of Health Sciences, 1 18 1 Kamiyoga, Setagaya Ku, Tokyo, Japan
    Mutat Res 444:269-81. 1999
    b>Procarbazine, a drug used for cancer chemotherapy, is carcinogenic in rodent bioassays...
  66. ncbi Advantage of post-radiotherapy chemotherapy with CCNU, procarbazine, and vincristine (mPCV) over chemotherapy with VM-26 and CCNU for malignant gliomas
    B Jeremic
    Department of Oncology, University Hospital, Kragujevac, Yugoslavia
    J Chemother 4:123-6. 1992
    ..36 AA and 31 GBM patients were treated with adjuvant chemotherapy consisting of CCNU 100 mg/m2 day 1, procarbazine 60 mg/m2 days 1-14, and vincristine 1.4 mg/m2 (max...
  67. ncbi The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochloride
    Stuart A Grossman
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland 21231 1000, and Massachusetts General Hospital, Boston, USA
    Clin Cancer Res 12:5174-81. 2006
    b>Procarbazine hydrochloride (PCB) is one of the few anticancer drugs with activity against high-grade gliomas...
  68. ncbi Inhibin B is superior to FSH as a serum marker for spermatogenesis in men treated for Hodgkin's lymphoma with chemotherapy during childhood
    Robert D van Beek
    Department of Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Room Sp3435, PO Box 2060, 3000 CB Rotterdam, The Netherlands
    Hum Reprod 22:3215-22. 2007
    ....
  69. ncbi Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin's lymphoma during childhood
    Robert D van Beek
    Department of Pediatric Hematology Oncology, Erasmus MC Rotterdam, The Netherlands
    J Clin Endocrinol Metab 92:3869-74. 2007
    ..The aim of this study was to evaluate the long-term effects of combination chemotherapy treatment for girls with Hodgkin's lymphoma (HL) on gonadal function using anti-Müllerian hormone (AMH) and inhibin B as ovarian reserve parameters...
  70. ncbi Survival in Hodgkin's disease patients--report of 25 years of experience at the Milan Cancer Institute
    Gianni Bonadonna
    Department of Medical Oncology, Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy
    Eur J Cancer 41:998-1006. 2005
    ..four randomised studies have been activated at the Milan Cancer Institute using nitrogen mustard, vincristine, procarbazine and prednisone (MOPP) and doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) regimens, with or without ..
  71. ncbi Long-term follow-up of salvage radiotherapy in Hodgkin's lymphoma after chemotherapy failure
    Belinda Campbell
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, St Andrew s Place, East Melbourne, Victoria, Australia
    Int J Radiat Oncol Biol Phys 63:1538-45. 2005
    ..To evaluate the long-term results of salvage radiotherapy (SRT) for Hodgkin's lymphoma after chemotherapy failure...
  72. ncbi ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi
    Paolo G Gobbi
    Medicina Interna e Oncologia Medica, Universita di Pavia, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S Matteo, Pavia, Italy
    J Clin Oncol 23:9198-207. 2005
    ..vincristine, bleomycin, etoposide, and prednisone (Stanford V) and mechlorethamine, vincristine, procarbazine, prednisone, epidoxirubicin, bleomycin, vinblastine, lomustine, doxorubicin, and vindesine (MOPPEBVCAD), were ..
  73. ncbi [Primary treatment of advanced Hodgkin's disease]
    Arpad Illes
    Debreceni Egyetem, Orvos és Egészségtudományi Centrum, Belgyógyászati Intézet III Belgyógyászati Klinika
    Orv Hetil 146:195-202. 2005
    ..The multicentre analysis to confirm these results and to compare them with standard scheme is still under way. It is to be hoped that risk adapted management for advanced stage Hodgkin's disease will also be available soon...
  74. ncbi Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin's lymphoma
    R Zanotti
    Department of Clinical and Experimental Medicine, Section of Hematology, University of Verona, Policlinico G B Rossi, Italy
    Ann Oncol 13:1908-14. 2002
    ..The aim of this study was to assess the prognostic power of the combined evaluation of sCD30 and IPS in these patients...
  75. ncbi Perspectives of the management of childhood lymphoma: experience at Tygerberg Hospital, Western Cape, South Africa
    Glynn Wessels
    Department of Paediatrics and Child Health, Stellenbosch University and Tygerberg Hospital, P O Box 19063, Tygerberg 7505, South Africa
    Transfus Apher Sci 32:27-31. 2005
    ..The majority of patients had stage III and IV disease. Although the LMB regimens are toxic, the implementation is manageable provided good laboratory back up and supportive facilities are available...
  76. ncbi [Features of clinical course of combination chemotherapy for liver involvement in Hodgkin's disease]
    L V Filatova
    Vopr Onkol 54:192-203. 2008
    ..The latter procedure should predominate in cases of initial extended involvement or as second-line chemotherapy designed to defeat drug resistance and improve end results...
  77. ncbi [Over 30-year experience of Polish Pediatric Leukemia/Lymphoma Study Group for treatment of Hodgkin's disease in children and adolescents: improvement curability and decrease of serious complications]
    Walentyna Balwierz
    Klinika Onkologii i Hematologii Dzieciecej Polsko Amerykańskiego Instytutu Pediatrii, Collegium Medicum Uniwersytetu Jagiellonskiego w Krakowie
    Przegl Lek 61:33-9. 2004
    ..In the first period the basic CT was MVPP (mechlorethamine, vinblastine, procarbazine, prednisone), while later B-DOPA (bleomycin, dacarbazine, vincristine, prednisone, doxorubicin) was gradually ..
  78. ncbi Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials
    M Sieniawski
    Department of Internal Medicine, University Hospital Cologne, Cologne, Germany
    Ann Oncol 19:1795-801. 2008
    ..Infertility is one of the most significant side-effects in long-term survivors of successfully treated Hodgkin's lymphoma (HL)...
  79. ncbi Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group
    Andreas Josting
    First Department of Internal Medicine, University Hospital Cologne, Joseph Stelzmann Str 9, 50924 Cologne, Germany
    J Clin Oncol 23:1522-9. 2005
    ..To evaluate treatment outcome and prognostic factors in patients with refractory or first relapsed Hodgkin's disease (HD) treated with salvage radiotherapy (SRT) alone...
  80. ncbi Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group
    Karolin Behringer
    First Department of Internal Medicine, University Hospital Cologne, Joseph Stelzmann Str 9, 50924 Cologne, Germany
    J Clin Oncol 23:7555-64. 2005
    ..Among these, infertility for female patients is of major importance. The subject of this analysis is to evaluate the menstrual status after HL therapy...
  81. ncbi [Limphomatous meningitis as recurrence site in Hodgkin's disease]
    Martín Greco
    Servicio de Clinica Medica, Hospital Juan A Fernandez, Buenos Aires
    Medicina (B Aires) 66:332-4. 2006
    ..There are less than 50 similar cases reported in the literature. We review the clinical features and differential diagnosis of leptomeningeal metastases in Hodgkin's disease...
  82. ncbi Clinical dose-volume histogram analysis in predicting radiation pneumonitis in Hodgkin's lymphoma
    Eng Siew Koh
    Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    Int J Radiat Oncol Biol Phys 66:223-8. 2006
    ..To quantify the incidence of radiation pneumonitis (RP) in a modern Hodgkin's lymphoma (HL) cohort, and to identify any clinically relevant parameters that may influence the risk of RP...
  83. ncbi Multicentre phase II study of the baseline BEACOPP regimen for patients with advanced-stage Hodgkin's lymphoma
    Nozomi Niitsu
    Hematology Division, Department of Internal Medicine, Saitama Medical University, 38 Morohongo, Moroyama, Iruma gun, Saitama, Japan
    Leuk Lymphoma 47:1908-14. 2006
    ..HL) study group designed the BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisolone) regimen...
  84. ncbi [Comparison of preliminary results of involved-field with extended field radiotherapy combined with chemotherapy for early stage Hodgkin's disease]
    Wei Hu Wang
    Department of Radiation Oncology, Cancer Institute Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China
    Zhonghua Zhong Liu Za Zhi 28:218-21. 2006
    ..To evaluate whether involved-field (IF) radiotherapy is equally effective and less toxic in comparison with extended-field (EF) radiotherapy for patients with early-stage Hodgkin's disease (HD) who received combined modality therapy...
  85. ncbi Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group
    B Klimm
    Department I of Internal Medicine, University Hospital Cologne, Germany
    Ann Oncol 18:357-63. 2007
    ..Since many of these patients receive combined modality treatment, we evaluated the impact of different radiation field sizes, that is extended-field (EF) or involved-field (IF) technique when given after four cycles of chemotherapy...
  86. ncbi [Ten-year outcomes of lymphogranulomatosis treatment according to the protocol MOPP-ABVD+radiotherapy]
    A V Pivnik
    Ter Arkh 78:57-62. 2006
    ....
  87. ncbi Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma
    Navneet S Majhail
    Blood and Marrow Transplant Program, Divisions of Medical and Pediatric Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
    Biol Blood Marrow Transplant 12:1065-72. 2006
    ..A risk-adapted approach should be followed in determining treatment options for patients with PR REF and REL HL...
  88. ncbi [Our experiences in treating patients with Hodgkin disease in the last decade]
    Zsofia Simon
    Debreceni Egyetem Orvos és Egészségtudományi Centrum, Belgyógyászati Intézet, III Belgyógyászati Klinika, Debrecen
    Orv Hetil 148:675-82. 2007
    ..Recently, in the diagnostics and treatment of Hodgkin's disease significant developments have occurred...
  89. ncbi Proliferative index and CD15 expression in pediatric classical Hodgkin lymphoma
    Veronique Dinand
    Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India
    Pediatr Blood Cancer 50:280-3. 2008
    ..This study was conducted to assess the clinical and prognostic significance of lack of CD15 expression, proliferative index (PI), and expression of tumor suppressor protein p53 in pediatric classical Hodgkin lymphoma (CHL)...
  90. ncbi Hodgkin's lymphoma in adolescents
    Lynda M Foltz
    Division of Hematology, Leukemia Bone Marrow Transplant Program of British Columbia, Vancouver, British Columbia, Canada
    J Clin Oncol 24:2520-6. 2006
    ..To compare the clinical presentation, response to treatment, and long-term outcome of Hodgkin's lymphoma (HL) presenting in adolescents and young adults...
  91. ncbi Survival improvement of young patients, aged 16-23, with Hodgkin lymphoma (HL) during the last three decades
    A A Koumarianou
    Second Department of Internal Medicine Propaedeutic, Medical Oncology Unit, Attikon University Hospital, Athens University, Rimini 1, 12462 Athens, Greece
    Anticancer Res 27:1191-7. 2007
    ..Current controversial issues surrounding this disease, including the role of radiotherapy, positron emission tomography (PET), bone marrow biopsy and stem cell transplantation are discussed...
  92. ncbi [Hodgkin lymphoma in Chile: experience of the national adult cancer program]
    M Elena Cabrera
    Hospital del Salvador, Santiago, Chile
    Rev Med Chil 135:341-50. 2007
    ..Hodgkin lymphoma is a highly curable disease...
  93. ncbi [Evolution in 18F-FDG-PET of a case of Hodgkin disease, nodular sclerosis variety, after treatment and autotrasplant]
    A Sánchez-Salmon
    Servicio de Medicina Nuclear, Complejo Hospitalario Universitario, Santiago de Compostela, La Coruna, Spain
    Rev Esp Med Nucl 26:165-8. 2007
    ..Both conditions, tumor and infection, were present in different times of the course. The integration of all the x-ray, clinical, laboratory and metabolic information allowed for a better and correct management of this patient...
  94. ncbi Hodgkin lymphoma among patients infected with HIV in post-HAART era
    Paula Yurie Tanaka
    Hematology Section, Emilio Ribas Infectology Institute, Sao Paulo, Brazil
    Clin Lymphoma Myeloma 7:364-8. 2007
    ..Despite that, the best treatment option is undefined...
  95. ncbi [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab]
    H K Al-Ali
    Abteilung Hämatologie Onkologie, Universitatsklinikum Leipzig, Leipzig, Germany
    Dtsch Med Wochenschr 132:1688-91. 2007
    ..We describe a patient with mixed cellularity (MC)-type HD with frequent relapses. As all Hodgkin's or Hogan-Reed-Sternberg (HRS) cells expressed CD20, treatment with the anti-CD20 monoclonal antibody rituximab was given...
  96. ncbi Benign pleural schwannoma secondary to radiotherapy for Hodgkin disease
    Stefania Morbidini-Gaffney
    Department of Radiation Oncology, Upstate Medical University, Syracuse, New York 13210, USA
    Am J Clin Oncol 28:640-1. 2005
  97. ncbi Significance of splenomegaly in childhood Hodgkin disease
    Laxman S Arya
    Department of Pediatrics, All India Institute of Medical Sciences, New Delhi 110 029, India
    J Pediatr Hematol Oncol 26:807-12. 2004
    ..The authors' purpose was to study the clinicoradiologic features and prognostic significance of splenomegaly and that of splenic involvement in childhood HD...
  98. ncbi A novel type of metastatically spreading subcutaneous aspergillosis without epidermal lesions following allogeneic stem cell transplantation
    O A Cornely
    Department I of Internal Medicine, Hematology, Oncology and Infectious Diseases, University of Cologne, Cologne, Germany
    Bone Marrow Transplant 28:899-901. 2001
    ..This case report describes a novel form of aspergillosis and underlines the need for an aggressive diagnostic approach in severely immunocompromised patients...
  99. ncbi Decreasing the number of MOPP courses reduces gonadal damage in survivors of childhood Hodgkin disease
    H van den Berg
    Department of Pediatric Oncology, Emma Children Hospital AMC, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Pediatr Blood Cancer 42:210-5. 2004
    ..RT) in combination with chemotherapy, the presumed detrimental effect of MOPP (mustine, vincristine, procarbazine, and prednisone) (in contrast to schemes with less or without alkylating agents) could not be discerned ..
  100. ncbi Impact of chest wall and lung invasion on outcome of stage I-II Hodgkin's lymphoma after combined modality therapy
    David C Hodgson
    Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada
    Int J Radiat Oncol Biol Phys 57:1374-81. 2003
    ..To examine the impact of extranodal chest wall and lung invasion on the prognosis of patients with clinical Stage I-II Hodgkin's lymphoma treated with combined modality therapy...
  101. ncbi Advanced Hodgkin's disease: ABVD is better, yet is not good enough!
    Volker Diehl
    J Clin Oncol 21:583-5. 2003

Research Grants20

  1. LEUKOCYTE, ENZYME AND DRUG CHEMILUMINESCENCE STUDIES
    JEFFREY KANOFSKY; Fiscal Year: 1990
    ..daunorubicin, carminic acid, mithramycin, chromomycin A3, olivomycin, mitomycin C, VP-16 streptonigrin, procarbazine, paraquat, cis-platinum and gossypol...
  2. Oral Chemotherapy in AIDS-related NHL in Uganda & Kenya
    Scot Remick; Fiscal Year: 2003
    ..combination chemotherapy regimen, consisting of lomustine (CCNU), etoposide (VP-16) cyclophosphamide and procarbazine, has been specifically developed for patients with AIDS-related non-Hodgkin's lymphoma (NHL)...
  3. ASSESSMENT OF GENETIC DAMAGE INDUCED BY CHEMOTHERAPY
    JAN LIANG; Fiscal Year: 1992
    ..These drugs include nitrogen, mustard, vincristine, procarbazine and prednisone (MOPP) and adriamycin, bleomycin, vinblastine and dacarbazine (ABVD)...
  4. MUTAGENIC ACTION OF CANCER THERAPY ON TESTIS CELLS
    Marvin Meistrich; Fiscal Year: 1992
    ..Testosterone treatment appears to protect spermatogenesis in the rat from cytotoxic damage by procarbazine (PCB) and radiation; however, the mechanism of protection is unknown...
  5. AGT DEPLETION FOR THERAPY OF CNS TUMORS
    Jennifer Quinn; Fiscal Year: 2004
    ..The nitrosoureas and methylators such as procarbazine were originally chosen for treatment of central nervous system tumors on the basis of favorable physiochemical ..
  6. DNA CROSSLINK REPAIR ENZYMES IN HUMAN CELLS
    THOMAS BRENT; Fiscal Year: 1992
    ..g., clomesome, mitozolomide, procarbazine, mitomycin C and cisplatin): We shall determine GATase activity in a variety of human tumor lines, in- cluding ..
  7. NUCLEOPROTEINS IN MAMMALIAN SPERMATOGENESIS
    Marvin Meistrich; Fiscal Year: 2006
    ..Thus they provide a well-defined model system for study of human infertility. ..
  8. NATIONAL GENE VECTOR LABORATORY AT INDIANA UNIVERSITY
    Kenneth Cornetta; Fiscal Year: 2007
    ..abstract_text> ..
  9. NABTC CENTRAL OPERATION GRANT (UCSF PROJECT LEADER)
    Michael Prados; Fiscal Year: 2008
    ..The NABTC will treat patients using novel therapeutic agents with the ultimate goal to increase quality, and hopefully, overall survival in this patient population. ..
  10. New Approaches to Brain Tumor Therapy, NABTT CNS
    Glenn Lesser; Fiscal Year: 2008
    ..We continue to expect that the novel observations which arise from these efforts will lead to improvements in both the overall survival and quality of life of our patients afflicted with these tumors. ..
  11. BLys inhibition using TACI-Fc in patients with B-bell non-Hodgkins' Lymphoma
    Stephen Ansell; Fiscal Year: 2008
    ..abstract_text> ..
  12. Participating Member Institution in NABTC
    Lisa DeAngelis; Fiscal Year: 2008
    ..abstract_text> ..
  13. MINORITY BASED COMMUNITY CLINICAL ONCOLOGY PROGRAM
    Peter Wiernik; Fiscal Year: 2006
    ..Efforts in screening and prevention intervention will be facilitated through the Community Outreach program and Community Council. ..
  14. PEDIATRIC ONCOLOGY GROUP
    Faith Kung; Fiscal Year: 2002
    ..Dr. Yu's laboratory will continue to explore new immunotherapeutic agents for Group use, and serve as the Group Reference Laboratory. We plan to continue our active participation in all phases of POG activities. ..
  15. Analysis Methods for Volume-Outcome Studies
    Katherine Panageas; Fiscal Year: 2005
    ..Our methodological research will heighten awareness of clustering in health policy studies. Upon completion of our research plan, we will make recommendations about various analytic strategies for clustered binary data. ..
  16. CHILDRENS CANCER GROUP
    RAYMOND HUTCHISON; Fiscal Year: 2002
    ..abstract_text> ..
  17. PEDIATRIC BRAIN TUMOR CLINICAL TRIAL CONSORTIUM
    Michael Prados; Fiscal Year: 2003
    ..The aim of these treatment approaches is to increase disease-free and overall survival in children with brain tumors. ..
  18. EARLY GENETIC EVENTS IN ASTROCYTOMA FORMATION
    JOHN HENSON; Fiscal Year: 2003
    ..As a way forward to new hypotheses, they will determine genome-wide changes in subsets of LGA patients with good and poor outcomes using comparative genomic hybridization (CGH). ..
  19. HEPATITIS C IN CHILDHOOD CANCER SURVIVORS
    Melissa Hudson; Fiscal Year: 2003
    ..abstract_text> ..
  20. NABTT-Consortium Therapeutic Studies of CNS Malignancies
    Stuart Grossman; Fiscal Year: 2008
    ..abstract_text> ..